Pfizer/BioNTech, Moderna Vaccines Take Baby Steps Into Booster Shots
Moderna may benefit from data indicating strong efficacy against the Delta strain, though an analyst pointed out that they come with some important caveats.
You may also be interested in...
While delays to manufacturing have frustrated the vaccine’s submission, Novavax is still confident its nanoparticle-based jab will play a significant role in COVID-19.
In this week's podcast edition of Five Must-Know Things: senior level changes at Lilly; mRNA COVID vaccines and booster shots; GSK and Sanofi deal with a changed vaccines landscape; a look ahead at new drugs for hematological malignancies; and a huge fundraising in China for an mRNA specialist.
Pfizer and BioNTech sent in Phase I data for a third dose of BNT162b2 to support future licensure, Gritstone bio will work with CEPI to develop its second-generation vaccine in South Africa and other areas, and Roche Genentech expects a shortage of the drug Actemra to last for several weeks amid a surge in cases.